TrialCompass TCL
Back to results
Phase 1, Phase 2RecruitingPriority 2 · High priorityNCT06810778

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is testing Duvelisib and Venetoclax for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 1 US location.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Duvelisib (DRUG): 15 and 25 mg BID | Venetoclax (DRUG): 200, 400, and 800 mg QD

Drugs / treatments
Duvelisib, Venetoclax
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT06810778

Phase: Phase 1, Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 1, Phase 2 trial is testing Duvelisib and Venetoclax for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 1 US location.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

Duvelisib (DRUG): 15 and 25 mg BID | Venetoclax (DRUG): 200, 400, and 800 mg QD

Drugs / treatments: Duvelisib, Venetoclax

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 12 patients

Primary endpoint: Determine the dose limiting toxicities (DLTs), for the combination regimen of duvelisib plus venetoclax for patients with relapsed or refractory PTCL; Determine the Maximum Tolerated Dose MTD); Recommended phase II dose (Phase I)

Ages: 18 Years to —

Start date: 2025-05-02 | Est. completion: 2031-06-01

Locations

1 US sites · 1 total

California

Contact

Vladimir Bonhomme | VBonhomme@mednet.ucla.edu | 310-794-6500

Sponsor: Jonsson Comprehensive Cancer Center (OTHER)

Tags

CTCL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06810778

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.